Cons: After lung stereotactic ablative radiotherapy for a peripheral stage I non-small cell lung...

Por Giuliani, Meredith, Bezjak, Andrea
Publicado no Transl Lung Cancer Res (2016)

Cons: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Por Nestle, Ursula, Belderbos, José
Publicado no Transl Lung Cancer Res (2015)

Pros: should a medically inoperable patient with a T2N0M0 non-small cell lung cancer central in the lung hilus be treated using stereotactic body radiotherapy?

Por Woodford, Katrina, Senthi, Sashendra
Publicado no Transl Lung Cancer Res (2015)

Pros: After stereotactic ablative radiotherapy for a peripheral early-stage non-small cell lung...

Por Nguyen, Timothy K., Palma, David A.
Publicado no Transl Lung Cancer Res (2016)

Immunotherapy meets targeted therapy: will this team end the war against cancer?

Por Morales-Espinosa, Daniela, García-Román, Silvia, Teixidó, Cristina, Karachaliou, Niki, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Endothelial Dll4-Notch signaling in tumor microenvironment: is there any hidden therapeutic opportunity?

Por Kumar, Amit, Desai, Sejal, Pandey, Badri N.
Publicado no Transl Lung Cancer Res (2013)

Pros: concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer

Por Rabatic, Bryan M., Kong, Feng-Ming (Spring)
Publicado no Transl Lung Cancer Res (2016)

Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor...

Por Brizzi, Maria Felice, Defilippi, Paola
Publicado no Transl Lung Cancer Res (2013)

Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer

Por Viteri, Santiago, González-Cao, María, Barrón, Feliciano, Riso, Aldo, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance

Por Remon, Jordi, Majem, Margarita
Publicado no Transl Lung Cancer Res (2013)

Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis

Por Chakravarti, Nitin, Prieto, Victor G.
Publicado no Transl Lung Cancer Res (2015)

Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way...

Por Pilotto, Sara, Molina-Vila, Miguel Angel, Karachaliou, Niki, Carbognin, Luisa, Viteri, Santiago, González-Cao, Maria, Bria, Emilio, Tortora, Giampaolo, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer

Por Pilotto, Sara, Carbognin, Luisa, Karachaliou, Niki, Garassino, Marina, Cuppone, Federica, Petraglia, Sandra, Rosell, Rafael, Tortora, Giampaolo, Bria, Emilio
Publicado no Transl Lung Cancer Res (2015)

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role

Por Santarpia, Mariacarmela, González-Cao, María, Viteri, Santiago, Karachaliou, Niki, Altavilla, Giuseppe, Rosell, Rafael
Publicado no Transl Lung Cancer Res (2015)

Translational Lung Cancer Research, the 7(th) AME Journal indexed in SCIE

Publicado no Transl Lung Cancer Res (2018)

Influence of chemotherapy on EGFR mutation status

Por Luo, Yung-Hung, Chen, Yuh-Min
Publicado no Transl Lung Cancer Res (2013)

Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?

Por Mountzios, Giannis
Publicado no Transl Lung Cancer Res (2018)

Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells

Por Lan, Dong, Wang, Li, He, Rongquan, Ma, Jie, Bin, Yehong, Chi, Xiaojv, Chen, Gang, Cai, Zhengwen
Publicado no Am J Transl Res (2018)

Can population data guide surveillance strategies for second primary lung cancers?

Por Arifin, Andrew J., Corkum, Mark T., Louie, Alexander V.
Publicado no Transl Lung Cancer Res (2018)

Can we use interleukin-1β blockade for lung cancer treatment?

Por Gottschlich, Adrian, Endres, Stefan, Kobold, Sebastian
Publicado no Transl Lung Cancer Res (2018)